StockNews.AI
DRMA
StockNews.AI
126 days

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

1. Dermata's XYNGARI(TM) shows significant efficacy in Phase 3 trial. 2. XYNGARI(TM) could be first weekly topical for moderate-to-severe acne.

3m saved
Insight
Article

FAQ

Why Bullish?

Significant efficacy data often leads to positive market reaction, as seen in similar biotech cases.

How important is it?

Strong trial results increase product viability, affecting investor sentiment positively.

Why Short Term?

Immediate market reactions typically occur following positive Phase 3 trial news.

Related Companies

KNSAVRNAXLRN
- Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial - - Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments - - XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™. XYNGARI™ Phase 3 STAR-1 Topline Week 4 Efficacy Results In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured timepoint) when compared to placebo.

Related News